CN101407511B - 一种结晶型的咪唑-5-羧酸衍生物 - Google Patents
一种结晶型的咪唑-5-羧酸衍生物 Download PDFInfo
- Publication number
- CN101407511B CN101407511B CN2007100941310A CN200710094131A CN101407511B CN 101407511 B CN101407511 B CN 101407511B CN 2007100941310 A CN2007100941310 A CN 2007100941310A CN 200710094131 A CN200710094131 A CN 200710094131A CN 101407511 B CN101407511 B CN 101407511B
- Authority
- CN
- China
- Prior art keywords
- formula
- polar solvent
- compound
- acid
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XMHJQQAKXRUCHI-UHFFFAOYSA-N CCCCc1nc(Cl)c(C(OCOC(OC(C)C)=O)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1 Chemical compound CCCCc1nc(Cl)c(C(OCOC(OC(C)C)=O)=O)[n]1Cc(cc1)ccc1-c(cccc1)c1-c1nnn[nH]1 XMHJQQAKXRUCHI-UHFFFAOYSA-N 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
2θ(°) | d值() | 相对强度I/I°(%) | 2θ(°) | d值() | 相对强度I/I°(%) |
6.92 | 12.77 | s | 12.02 | 7.36 | m |
13.90 | 6.37 | m | 14.58 | 6.07 | m |
15.18 | 5.83 | m | 16.60 | 5.33 | m |
17.56 | 5.05 | m | 18.42 | 4.81 | m |
18.94 | 4.68 | m | 20.26 | 4.38 | m |
20.88 | 4.25 | m | 22.08 | 4.02 | m |
23.10 | 3.85 | m | 23.46 | 3.79 | m |
24.14 | 3.68 | m | 24.40 | 3.64 | m |
25.16 | 3.53 | m | 25.74 | 3.46 | m |
26.32 | 3.38 | m | 26.66 | 3.34 | m |
27.14 | 3.28 | vs | 27.80 | 3.21 | m |
29.40 | 3.04 | m | 30.36 | 2.94 | w |
30.84 | 2.90 | w | 32.12 | 2.78 | w |
35.18 | 2.55 | w | 35.74 | 2.51 | w |
36.00 | 2.49 | w | 36.64 | 2.45 | w |
37.28 | 2.41 | w | 39.38 | 2.29 | w |
41.18 | 2.19 | w | 42.56 | 2.12 | w |
44.16 | 2.05 | w | 44.46 | 2.04 | w |
46.42 | 1.95 | w |
波长(cm-1) | 透光率(%) | 波长(cm-1) | 透光率(%) |
763 | 52 | 837 | 40 |
906 | 45 | 941 | 57 |
987 | 41 | 1020 | 67 |
1074 | 55 | 1136 | 52 |
1159 | 51 | 1256 | 71 |
1383 | 45 | 1410 | 43 |
1458 | 52 | 1483 | 47 |
1518 | 48 | 1732 | 71 |
1759 | 77 | 2871 | 41 |
2907 | 40 | 2934 | 42 |
2955 | 44 | 2987 | 43 |
Claims (14)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100941310A CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
US12/682,561 US8178569B2 (en) | 2007-10-11 | 2008-10-10 | Crystalline imidazole-5-carboxylic acid derivative |
EP08838798.0A EP2213669B1 (en) | 2007-10-11 | 2008-10-10 | Crystalline imidazol-5-carboxylic acid derivate |
PCT/CN2008/001715 WO2009049495A1 (fr) | 2007-10-11 | 2008-10-10 | Dérivé acide imidazol-5-carboxylique cristallin |
PL08838798T PL2213669T3 (pl) | 2007-10-11 | 2008-10-10 | Krystaliczna pochodna kwasu imidazolo-5-karboksylowego |
JP2010528263A JP5303765B2 (ja) | 2007-10-11 | 2008-10-10 | 結晶性イミダゾール−5−カルボン酸誘導体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100941310A CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101407511A CN101407511A (zh) | 2009-04-15 |
CN101407511B true CN101407511B (zh) | 2013-01-09 |
Family
ID=40566990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100941310A Active CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8178569B2 (zh) |
EP (1) | EP2213669B1 (zh) |
JP (1) | JP5303765B2 (zh) |
CN (1) | CN101407511B (zh) |
PL (1) | PL2213669T3 (zh) |
WO (1) | WO2009049495A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024643A (zh) | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
CN101317842A (zh) * | 2007-06-07 | 2008-12-10 | 上海艾力斯医药科技有限公司 | 一种咪唑-5-羧酸衍生物的治疗用途 |
CN103012377A (zh) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | 一种咪唑-5-羧酸酯的重结晶方法 |
CN104610232B (zh) * | 2013-11-01 | 2019-09-20 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN103965171A (zh) * | 2014-04-30 | 2014-08-06 | 上海艾力斯医药科技有限公司 | 一种阿利沙坦酯的制备方法 |
CN106188012B (zh) * | 2014-06-20 | 2018-11-30 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物 |
CN109694369B (zh) * | 2017-10-24 | 2023-02-14 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯盐晶型及含有所述盐晶型的药物组合物 |
CN114163391B (zh) * | 2021-12-14 | 2024-02-02 | 迪嘉药业集团股份有限公司 | 一种坎地沙坦中间体及坎地沙坦的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5298519A (en) * | 1991-10-04 | 1994-03-29 | Chemish Pharmazeutische Forschungsgesellschaft M.B.H. | Acylals of imidazole-5-carboxylic acid derivatives, and their use as angiotensin (II) inhibitors |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011646A2 (en) * | 2003-07-31 | 2005-02-10 | Nicox S.A. | Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases |
CA2671816C (en) | 2006-12-06 | 2012-06-05 | Shanghai Allist Pharmaceutical., Inc. | Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same |
-
2007
- 2007-10-11 CN CN2007100941310A patent/CN101407511B/zh active Active
-
2008
- 2008-10-10 US US12/682,561 patent/US8178569B2/en not_active Expired - Fee Related
- 2008-10-10 PL PL08838798T patent/PL2213669T3/pl unknown
- 2008-10-10 JP JP2010528263A patent/JP5303765B2/ja not_active Expired - Fee Related
- 2008-10-10 WO PCT/CN2008/001715 patent/WO2009049495A1/zh active Application Filing
- 2008-10-10 EP EP08838798.0A patent/EP2213669B1/en not_active Not-in-force
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5298519A (en) * | 1991-10-04 | 1994-03-29 | Chemish Pharmazeutische Forschungsgesellschaft M.B.H. | Acylals of imidazole-5-carboxylic acid derivatives, and their use as angiotensin (II) inhibitors |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20100292286A1 (en) | 2010-11-18 |
CN101407511A (zh) | 2009-04-15 |
EP2213669A1 (en) | 2010-08-04 |
EP2213669B1 (en) | 2015-07-29 |
US8178569B2 (en) | 2012-05-15 |
EP2213669A9 (en) | 2011-05-04 |
JP2011500515A (ja) | 2011-01-06 |
EP2213669A4 (en) | 2011-02-16 |
JP5303765B2 (ja) | 2013-10-02 |
WO2009049495A1 (fr) | 2009-04-23 |
PL2213669T3 (pl) | 2015-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101407511B (zh) | 一种结晶型的咪唑-5-羧酸衍生物 | |
EP2409975B1 (en) | Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound | |
JP3810079B2 (ja) | 微粉化ネビボロールを含有する組成物 | |
CN102405219A (zh) | 用于治疗copd的5-吡唑基-2-吡啶酮衍生物的对甲苯磺酸盐 | |
CN101304731A (zh) | 醋酸苯卓昔芬制剂及其生产方法 | |
KR20010074472A (ko) | 신규의 결정질 형태의 항바이러스성 벤즈이미다졸 화합물 | |
CN104017031A (zh) | 降血糖药物和组合物 | |
CN104031098A (zh) | 降糖药物 | |
CN107661302A (zh) | 一种口服固体制剂及其应用 | |
CN102958926B (zh) | 抗组胺剂 | |
CN101597272B (zh) | 艾拉莫德的钾盐化合物,其制备方法和药物应用 | |
CN103724374B (zh) | 一种苯磷硫胺化合物及制备方法及其含有该化合物的药物组合物 | |
AU2018296476B2 (en) | Pharmaceutical composition and method for preparing same | |
CN104721828A (zh) | 一种改善晶体药物稳定性的药物组合物及其制备方法 | |
CN101993417B (zh) | 磷酸二甲啡烷的稳定晶型 | |
CN106943356B (zh) | 一种泛昔洛韦缓释颗粒剂及其制备方法 | |
CN104817557A (zh) | 一种盐酸莫西沙星的稳定晶型及其制备方法 | |
CN105481758A (zh) | 一种洛美他派晶型ⅰ及其制备方法和用途 | |
CN115403538B (zh) | 一种依帕司他晶型及其制备方法和应用 | |
CN101333189A (zh) | 适合药用的阿立哌唑晶型、制备方法及药物组合物 | |
CN104098575B (zh) | 一种盐酸依匹斯汀晶型及其制备方法和用途 | |
CN105399725A (zh) | 曲格列汀化合物其盐、晶体、药物组合物和用途 | |
CN104257617A (zh) | 盐酸伊托必利口服制剂 | |
KR100837843B1 (ko) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 | |
CN109824569A (zh) | 一种西罗多辛晶型i及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ALLIS BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIS MEDICAL TECHNOLOGY CO., LTD. Effective date: 20090918 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090918 Address after: Zhou Zhu Road, Shanghai, Pudong New Area No. 337 Applicant after: Shanghai Allist Pharmaceuticals, Inc. Address before: Floor 1118, 5 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIST BIOMEDICAL CO., LTD. Effective date: 20121221 Owner name: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Effective date: 20121221 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201318 PUDONG NEW AREA, SHANGHAI TO: 201203 PUDONG NEW ZONE, SHANGHAI CITY Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW ZONE, SHANGHAI CITY TO: 518040 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121221 Address after: 518040 Shenzhen City, Futian District Shennan Road south of Anhui building 1921 Patentee after: Shenzhen Xinlitai Asset Management Co.,Ltd. Address before: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. Effective date of registration: 20121221 Address after: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor Patentee after: SHANGHAI ALLIST PHARMACEUTICALS, Inc. Address before: 201318 Shanghai city Pudong New Area Zhu Zhou Road No. 337 Patentee before: Shanghai Allist Pharmaceuticals, Inc. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090415 Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020458 Denomination of invention: Crystal type glyoxaline-5-carboxyl acid derivative License type: Common License Record date: 20121227 Application publication date: 20090415 Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020457 Denomination of invention: Crystal type glyoxaline-5-carboxyl acid derivative License type: Common License Record date: 20121227 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020457 Date of cancellation: 20150127 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: HUIZHOU XINLITAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Effective date: 20150717 Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Effective date: 20150717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150717 Address after: 516083, No. 42, West Petrochemical Avenue, Dayawan West, Huizhou, Guangdong, Huizhou Patentee after: HUIZHOU XINLITAI PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518040 Shenzhen City, Futian District Shennan Road south of Anhui building 1921 Patentee before: Shenzhen Xinlitai Asset Management Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Lu Wan Document name: Notification of Conformity |
|
DD01 | Delivery of document by public notice |